Clinical Trials Sponsored by Argus Pharmaceuticals

Total 19576 results

Argus Pharmaceuticals

Completed

A Study of Nystatin in HIV-Infected Patients

HIV Infections

United States
Arcus Biosciences, Inc.
Infinity Pharmaceuticals, Inc.

Completed

A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies

Ovarian Cancer | TNBC - Triple-Negative Breast Cancer

United States, Australia
Argus Pharmaceuticals

Completed

A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection.

HIV Infections

United States
Argus Pharmaceuticals

Completed

Pharmacokinetics of Nystatin LF I.V. in Patients With Acquired Immune Deficiency Syndrome-Related Complex (ARC)

HIV Infections

United States
Argos Therapeutics

Terminated

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

Israel, Spain, United States, Czechia, Canada, Italy, Hungary, United Kingdom
Argos Therapeutics

Completed

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

HIV Infection

United States, Canada
Arcus Biosciences, Inc.

Recruiting

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25)

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Bladder Cancer | Advanced Cancer | Non-Small Cell Lung Cancer (NSCLC) | Advanced Malignancies | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Gastroesophageal-junction...

United States
Arcus Biosciences, Inc.

Recruiting

A Phase 1 Study of AB521 in Renal Cell Carcinoma and Other Solid Tumors (ARC-20)

Clear Cell Renal Cell Carcinoma | Solid Tumors

Korea, Republic of, United States
Argos Therapeutics

Completed

Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC

Kidney Cancer | Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer

Renal Cell Carcinoma

Canada, United States
Argos Therapeutics

Completed

A Single-Patient Study Using AGS 006

Pancreatic Cancer

United States
Argos Therapeutics

Completed

Phase II Study of AGS-004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

HIV Infections

Canada, United States
Argos Therapeutics

Completed

An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus (SLE)

United States
Argos Therapeutics

Terminated

A Rollover Protocol for Subjects Previously Treated With AGS-003

Renal Cell Carcinoma

United States
Argos Therapeutics

Completed

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

Renal Cell Carcinoma

United States, Canada
Argos Therapeutics

Completed

RNA-Loaded Dendritic Cell Cancer Vaccine

Renal Cell Carcinoma

United States, Canada
Exelixis
Arcus Biosciences, Inc.

Recruiting

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

United States
Arcus Biosciences, Inc.

Recruiting

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies (ARC-27)

Advanced Cancer

United States
Arcus Biosciences, Inc.

Completed

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers (ARC-14)

Healthy Participants

Netherlands
Arcus Biosciences, Inc.

Completed

A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers (ARC-28)

Healthy Participants

United States
Arcus Biosciences, Inc.

Completed

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Melanoma | Renal Cell Carcinoma | Breast Cancer | Colorectal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Castration-resistant Prostate Cancer | Merkel Cell Carcinoma | GastroEsophageal Cancer

United States, Australia
Arcus Biosciences, Inc.

Completed

A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants

Healthy Participants

United States
Arcus Biosciences, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies (ARC-8)

Advanced Pancreatic Cancer

United States
Arcus Biosciences, Inc.

Completed

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers (ARC-26)

Cancer

United Kingdom
Arcus Biosciences, Inc.

Completed

A Study to Investigate the Safety of AB680 in Healthy Volunteers

Healthy Volunteers

Australia
Arcus Biosciences, Inc.

Completed

A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers

Healthy Volunteers

Australia
Arcus Biosciences, Inc.

Completed

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Colorectal Cancer | GastroEsophageal Cancer

United States, Australia
Mennatallah Arous Mohamed

Recruiting

Evaluation of Different Imaging Modalities in Regional Lymph Nodes Staging in Patients With Breast Cancer

Breast Carcinoma Metastatic in Lymph Node

Egypt
Arcus Biosciences, Inc.
Gilead Sciences

Completed

A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants

Healthy Participants

United States
AstraZeneca
Arcus Biosciences, Inc.

Recruiting

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

Non-Small Cell Lung Cancer

Korea, Republic of, Philippines, United States, Belgium, Hungary, India, Norway, United Kingdom, France, Canada, Germany, Japan, Malaysia, Taiwan, Greece, Italy, Mexico, Turkey, South Africa, Chile, Spain, Switzerland, Poland, Brazil, R... and more
Duke University
Argos Therapeutics

Terminated

RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)

Metastatic Renal Cell Carcinoma | Genitourinary Cancer (Bladder, Prostate or Testicular)

United States
Angus Yu

Completed

Effectiveness of Tai Chi Training on Metabolic Syndrome

Metabolic Syndrome

Hong Kong
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer (STAR-121)

Non-small Cell Lung Cancer

Taiwan, Hong Kong, United States, Netherlands, United Kingdom, Italy, Korea, Republic of, Spain, Israel, Japan, France, Portugal, China, Turkey, Brazil, Mexico, Austria, Germany, Belgium, Chile, Argentina, Singapore, Canada
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

Philippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)

Prostatic Neoplasms, Castration-Resistant | Prostatic Cancer, Castration-Resistant | Castration Resistant Prostatic Neoplasms | Androgen-Resistant Prostatic Neoplasms

United States, Canada
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
Arcus Biosciences, Inc.
Gilead Sciences

Completed

A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer

Healthy Participants

Netherlands
Surface Oncology
Arcus Biosciences, Inc.

Completed

Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Arcus Biosciences, Inc.
Gilead Sciences

Recruiting

Study With Immunotherapy Combinations in Participants With Metastatic Non-Small Cell Lung Cancer (EDGE-Lung)

Advanced Non-Small Cell Lung Cancer

United States, Australia, Korea, Republic of
Arcus Biosciences, Inc.
Gilead Sciences

Recruiting

A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body (STAR-221)

Advanced Upper Gastrointestinal Tract Adenocarcinoma

United States, France, Spain, Korea, Republic of, Hungary, Israel, Italy, Japan, United Kingdom, Australia, Canada, Portugal, Romania, Hong Kong, Malaysia, Argentina, Georgia, Serbia, Lithuania, Mexico, Chile, Greece, Guatemala, Phili... and more
Arcus Biosciences, Inc.
Gilead Sciences

Recruiting

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Gastrointestinal Tract Malignancies

United States, Korea, Republic of, France, Serbia, Canada
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12)

Melanoma | Lymphoma, Non-Hodgkin | Cervical Cancer | Multiple Myeloma | Gastric Cancer | Esophageal Cancer | Advanced Solid Tumor | Gastroesophageal Junction Adenocarcinoma | Non Small Cell Lung Cancer (NSCLC) | Diffuse Large B Cell Lymphoma (DLBCL)

United States, Spain, Poland
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4)

Non Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | Non Small Cell Lung Cancer Metastatic | Sensitizing EGFR Gene Mutation

United States, Korea, Republic of, Singapore, Taiwan
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Solid Tumor, Unspecified, Adult

United States, Australia
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. (ARC-9)

Metastatic Colorectal Cancer

Spain, United States, Korea, Republic of, France, United Kingdom, Italy
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Angus W. Thomson PhD DSc

Active, not recruiting

Delayed Infusion of DCreg in Living Donor Liver Transplantation

Living Donor Liver Transplantation

United States

Clinical Trials Sponsored by Argus Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations